MOTS-c vs SS-31

MOTS-c and SS-31 are both research peptides studied across multiple applications, yet they operate through fundamentally different mechanisms. MOTS-c, a mitochondrial-derived peptide, primarily influences metabolic regulation via AMPK activation, while SS-31 targets mitochondrial structure by stabilizing cardiolipin. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.

Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.

SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane, binding to cardiolipin and stabilizing cristae structure. It is being developed by Stealth BioTherapeutics for mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. It has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome.Developed by Stealth BioTherapeutics, it has been investigated for mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. SS-31 has undergone multiple Phase I–III clinical trials, including the TAZPOWER trial for Barth syndrome. Research suggests it improves mitochondrial function, reduces cardiac dysfunction, and holds potential anti-aging effects. Its clinical development provides a stronger evidence base compared to MOTS-c, with demonstrated tolerability in human subjects.

Both peptides are studied for metabolic health and anti-aging, though their approaches differ. MOTS-c research focuses on metabolic regulation, insulin sensitivity, and exercise mimetics, while SS-31 targets mitochondrial dysfunction and cardiac health. Neither peptide has unique applications beyond these shared areas, but their distinct mechanisms offer complementary research avenues. For example, MOTS-c may be more relevant for metabolic disorders, whereas SS-31 could be prioritized for mitochondrial diseases or cardiac conditions.

MOTS-c: No adverse effects have been reported in preclinical animal studies. However, human tolerability is completely unknown for native MOTS-c, as no human trials have been completed. The modified analog CB4211 showed good tolerability in a Phase 1 trial, but this does not directly reflect the safety profile of the native peptide. SS-31: Generally well-tolerated in clinical trials at tested doses. Common side effects include injection site reactions (pain, redness), mild headache, dizziness, and nausea. The extensive clinical data for SS-31 provides a more robust safety profile compared to MOTS-c.